<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00969111</url>
  </required_header>
  <id_info>
    <org_study_id>UFPTI 0902-PR06</org_study_id>
    <nct_id>NCT00969111</nct_id>
  </id_info>
  <brief_title>Postoperative or Salvage Radiotherapy (RT) for Node Negative Prostate Cancer Following Radical Prostatectomy</brief_title>
  <acronym>PR06</acronym>
  <official_title>Postoperative or Salvage Radiotherapy for Node Negative Prostate Cancer Following Radical Prostatectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Florida</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Florida</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to see what effects, good and/or bad, proton radiation, and/or
      conventional radiation and hormonal therapy (if applicable), has on prostate cancer that has
      already returned or the risk of prostate cancer returning.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2009</start_date>
  <completion_date type="Anticipated">August 2050</completion_date>
  <primary_completion_date type="Anticipated">August 2031</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The treatment-related rate of acute grade 3 gastrointestinal and genitourinary toxicity following treatment with proton based radiation therapy.</measure>
    <time_frame>6 months after the end of radiation therapy</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Collect and analyze quality of life, treatment-related morbidity, disease control and survival outcome parameters</measure>
    <time_frame>After radiation: every 6 months for 3 years, then annually for 20 years</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Postop Non-High Risk</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Proton to 66.6 CGE</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Postop High Risk</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IMRT to 45 Gy; prostate bed proton boost of 21.6 CGE</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Salvage Non-High Risk</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Proton to 70.2 CGE</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Salvage High Risk</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IMRT to 45 Gy; proton boost to prostate bed to 25.2 CGE</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>IMRT to 45 Gy; prostate bed proton boost of 21.6 CGE</intervention_name>
    <description>Postop High Risk</description>
    <arm_group_label>Postop High Risk</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Proton (prostate bed) to 70.2 CGE</intervention_name>
    <description>Salvage Non-High Risk</description>
    <arm_group_label>Salvage Non-High Risk</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>IMRT to 45 Gy; proton boost to prostate bed to 25.2 CGE</intervention_name>
    <description>Salvage High Risk</description>
    <arm_group_label>Salvage High Risk</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Proton to 66.6 CGE</intervention_name>
    <description>Post-Op Non High Risk</description>
    <arm_group_label>Postop Non-High Risk</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Prostate cancer treated primarily with open, laparoscopic or robotically assisted
             prostatectomy.

          -  Maximum PSA value of 20 ng/ml.

        Exclusion Criteria:

          -  Evidence of distant metastasis (M1).

          -  Prior systemic chemotherapy for any reason.

          -  Previous irradiation to the pelvis that would compromise the ability to deliver the
             prescribed study treatment.

          -  Active inflammatory bowel disease (Crohn's disease, diverticulitis or ulcerative
             colitis) affecting the rectum. (Non-active diverticulitis and Crohn's disease not
             affecting the rectum are allowed).

          -  History of hip replacement.

          -  Prior or concurrent cancer, other than non-melanomatous skin cancer, unless disease
             free for at least 5 years.

          -  Taking Saw Palmetto or methotrexate and unable or unwilling to discontinue its use
             during radiation.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Randal H Henderson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Florida Proton Therapy Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Intake Coordinator</last_name>
    <phone>877-686-6009</phone>
  </overall_contact>
  <location>
    <facility>
      <name>University of Florida Proton Therapy Institute</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32206</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Intake Coordinator</last_name>
      <phone>877-686-6009</phone>
    </contact>
    <investigator>
      <last_name>Randal H Henderson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.floridaproton.org/contact/contact.html</url>
    <description>Contact the University of Florida Proton Therapy Institute</description>
  </link>
  <reference>
    <citation>American Cancer Society. 2007. Ref Type: Electronic Citation</citation>
  </reference>
  <reference>
    <citation>Thompson IM Jr, Tangen CM, Paradelo J, Lucia MS, Miller G, Troyer D, Messing E, Forman J, Chin J, Swanson G, Canby-Hagino E, Crawford ED. Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial. JAMA. 2006 Nov 15;296(19):2329-35.</citation>
    <PMID>17105795</PMID>
  </reference>
  <reference>
    <citation>Bott SR, Freeman AA, Stenning S, Cohen J, Parkinson MC. Radical prostatectomy: pathology findings in 1001 cases compared with other major series and over time. BJU Int. 2005 Jan;95(1):34-9.</citation>
    <PMID>15638892</PMID>
  </reference>
  <reference>
    <citation>Thompson IM, Tangen CM, Paradelo J, Lucia MS, Miller G, Troyer D, Messing E, Forman J, Chin J, Swanson G, Canby-Hagino E, Crawford ED. Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial. J Urol. 2009 Mar;181(3):956-62. doi: 10.1016/j.juro.2008.11.032. Epub 2009 Jan 23.</citation>
    <PMID>19167731</PMID>
  </reference>
  <reference>
    <citation>Bolla M, van Poppel H, Collette L, van Cangh P, Vekemans K, Da Pozzo L, de Reijke TM, Verbaeys A, Bosset JF, van Velthoven R, Maréchal JM, Scalliet P, Haustermans K, Piérart M; European Organization for Research and Treatment of Cancer. Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911). Lancet. 2005 Aug 13-19;366(9485):572-8.</citation>
    <PMID>16099293</PMID>
  </reference>
  <reference>
    <citation>Bianco FJ Jr, Scardino PT, Eastham JA. Radical prostatectomy: long-term cancer control and recovery of sexual and urinary function (&quot;trifecta&quot;). Urology. 2005 Nov;66(5 Suppl):83-94.</citation>
    <PMID>16194712</PMID>
  </reference>
  <reference>
    <citation>Stephenson AJ, Scardino PT, Kattan MW, Pisansky TM, Slawin KM, Klein EA, Anscher MS, Michalski JM, Sandler HM, Lin DW, Forman JD, Zelefsky MJ, Kestin LL, Roehrborn CG, Catton CN, DeWeese TL, Liauw SL, Valicenti RK, Kuban DA, Pollack A. Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J Clin Oncol. 2007 May 20;25(15):2035-41. Erratum in: J Clin Oncol. 2007 Sep 10;25(26):4153.</citation>
    <PMID>17513807</PMID>
  </reference>
  <reference>
    <citation>Dearnaley DP, Hall E, Lawrence D, Huddart RA, Eeles R, Nutting CM, Gadd J, Warrington A, Bidmead M, Horwich A. Phase III pilot study of dose escalation using conformal radiotherapy in prostate cancer: PSA control and side effects. Br J Cancer. 2005 Feb 14;92(3):488-98.</citation>
    <PMID>15685244</PMID>
  </reference>
  <reference>
    <citation>Pollack A, Zagars GK, Starkschall G, Antolak JA, Lee JJ, Huang E, von Eschenbach AC, Kuban DA, Rosen I. Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys. 2002 Aug 1;53(5):1097-105.</citation>
    <PMID>12128107</PMID>
  </reference>
  <reference>
    <citation>Sathya JR, Davis IR, Julian JA, Guo Q, Daya D, Dayes IS, Lukka HR, Levine M. Randomized trial comparing iridium implant plus external-beam radiation therapy with external-beam radiation therapy alone in node-negative locally advanced cancer of the prostate. J Clin Oncol. 2005 Feb 20;23(6):1192-9.</citation>
    <PMID>15718316</PMID>
  </reference>
  <reference>
    <citation>Shipley WU, Verhey LJ, Munzenrider JE, Suit HD, Urie MM, McManus PL, Young RH, Shipley JW, Zietman AL, Biggs PJ, et al. Advanced prostate cancer: the results of a randomized comparative trial of high dose irradiation boosting with conformal protons compared with conventional dose irradiation using photons alone. Int J Radiat Oncol Biol Phys. 1995 Apr 30;32(1):3-12.</citation>
    <PMID>7721636</PMID>
  </reference>
  <reference>
    <citation>Zietman AL, DeSilvio ML, Slater JD, Rossi CJ Jr, Miller DW, Adams JA, Shipley WU. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. JAMA. 2005 Sep 14;294(10):1233-9. Erratum in: JAMA. 2008 Feb 27;299(8):899-900.</citation>
    <PMID>16160131</PMID>
  </reference>
  <reference>
    <citation>Swanson GP, Hussey MA, Tangen CM, Chin J, Messing E, Canby-Hagino E, Forman JD, Thompson IM, Crawford ED; SWOG 8794. Predominant treatment failure in postprostatectomy patients is local: analysis of patterns of treatment failure in SWOG 8794. J Clin Oncol. 2007 Jun 1;25(16):2225-9.</citation>
    <PMID>17538167</PMID>
  </reference>
  <reference>
    <citation>King CR, Kapp DS. Radiotherapy after prostatectomy: is the evidence for dose escalation out there? Int J Radiat Oncol Biol Phys. 2008 Jun 1;71(2):346-50. doi: 10.1016/j.ijrobp.2007.10.008. Epub 2008 Jan 30. Review.</citation>
    <PMID>18234451</PMID>
  </reference>
  <reference>
    <citation>King CR, Spiotto MT. Improved outcomes with higher doses for salvage radiotherapy after prostatectomy. Int J Radiat Oncol Biol Phys. 2008 May 1;71(1):23-7. doi: 10.1016/j.ijrobp.2007.09.047. Epub 2008 Jan 22.</citation>
    <PMID>18207668</PMID>
  </reference>
  <reference>
    <citation>Feng M, Hanlon AL, Pisansky TM, Kuban D, Catton CN, Michalski JM, Zelefsky MJ, Kupelian PA, Pollack A, Kestin LL, Valicenti RK, DeWeese TL, Sandler HM. Predictive factors for late genitourinary and gastrointestinal toxicity in patients with prostate cancer treated with adjuvant or salvage radiotherapy. Int J Radiat Oncol Biol Phys. 2007 Aug 1;68(5):1417-23. Epub 2007 Apr 6.</citation>
    <PMID>17418972</PMID>
  </reference>
  <reference>
    <citation>Vargas C, Fryer A, Mahajan C, Indelicato D, Horne D, Chellini A, McKenzie C, Lawlor P, Henderson R, Li Z, Lin L, Olivier K, Keole S. Dose-volume comparison of proton therapy and intensity-modulated radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2008 Mar 1;70(3):744-51. Epub 2007 Sep 27.</citation>
    <PMID>17904306</PMID>
  </reference>
  <reference>
    <citation>Slater JD, Rossi CJ Jr, Yonemoto LT, Bush DA, Jabola BR, Levy RP, Grove RI, Preston W, Slater JM. Proton therapy for prostate cancer: the initial Loma Linda University experience. Int J Radiat Oncol Biol Phys. 2004 Jun 1;59(2):348-52.</citation>
    <PMID>15145147</PMID>
  </reference>
  <reference>
    <citation>Partin AW, Mangold LA, Lamm DM, Walsh PC, Epstein JI, Pearson JD. Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium. Urology. 2001 Dec;58(6):843-8.</citation>
    <PMID>11744442</PMID>
  </reference>
  <reference>
    <citation>Spiotto MT, Hancock SL, King CR. Radiotherapy after prostatectomy: improved biochemical relapse-free survival with whole pelvic compared with prostate bed only for high-risk patients. Int J Radiat Oncol Biol Phys. 2007 Sep 1;69(1):54-61. Epub 2007 Apr 24.</citation>
    <PMID>17459606</PMID>
  </reference>
  <reference>
    <citation>Bolla M, Collette L, Blank L, Warde P, Dubois JB, Mirimanoff RO, Storme G, Bernier J, Kuten A, Sternberg C, Mattelaer J, Lopez Torecilla J, Pfeffer JR, Lino Cutajar C, Zurlo A, Pierart M. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet. 2002 Jul 13;360(9327):103-6.</citation>
    <PMID>12126818</PMID>
  </reference>
  <reference>
    <citation>Crook J, Ludgate C, Malone S, Lim J, Perry G, Eapen L, Bowen J, Robertson S, Lockwood G. Report of a multicenter Canadian phase III randomized trial of 3 months vs. 8 months neoadjuvant androgen deprivation before standard-dose radiotherapy for clinically localized prostate cancer. Int J Radiat Oncol Biol Phys. 2004 Sep 1;60(1):15-23.</citation>
    <PMID>15337535</PMID>
  </reference>
  <reference>
    <citation>D'Amico AV, Manola J, Loffredo M, Renshaw AA, DellaCroce A, Kantoff PW. 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial. JAMA. 2004 Aug 18;292(7):821-7.</citation>
    <PMID>15315996</PMID>
  </reference>
  <reference>
    <citation>Hanks GE, Pajak TF, Porter A, Grignon D, Brereton H, Venkatesan V, Horwitz EM, Lawton C, Rosenthal SA, Sandler HM, Shipley WU; Radiation Therapy Oncology Group. Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92-02. J Clin Oncol. 2003 Nov 1;21(21):3972-8. Erratum in: J Clin Oncol. 2004 Jan 15;22(2):386.</citation>
    <PMID>14581419</PMID>
  </reference>
  <reference>
    <citation>Pilepich MV, Winter K, John MJ, Mesic JB, Sause W, Rubin P, Lawton C, Machtay M, Grignon D. Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys. 2001 Aug 1;50(5):1243-52.</citation>
    <PMID>11483335</PMID>
  </reference>
  <reference>
    <citation>Pilepich MV, Winter K, Lawton CA, Krisch RE, Wolkov HB, Movsas B, Hug EB, Asbell SO, Grignon D. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma--long-term results of phase III RTOG 85-31. Int J Radiat Oncol Biol Phys. 2005 Apr 1;61(5):1285-90.</citation>
    <PMID>15817329</PMID>
  </reference>
  <reference>
    <citation>Roach M 3rd, DeSilvio M, Lawton C, Uhl V, Machtay M, Seider MJ, Rotman M, Jones C, Asbell SO, Valicenti RK, Han S, Thomas CR Jr, Shipley WS; Radiation Therapy Oncology Group 9413. Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: Radiation Therapy Oncology Group 9413. J Clin Oncol. 2003 May 15;21(10):1904-11.</citation>
    <PMID>12743142</PMID>
  </reference>
  <reference>
    <citation>Denham JW, Steigler A, Lamb DS, Joseph D, Mameghan H, Turner S, Matthews J, Franklin I, Atkinson C, North J, Poulsen M, Christie D, Spry NA, Tai KH, Wynne C, Duchesne G, Kovacev O, D'Este C; Trans-Tasman Radiation Oncology Group. Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial. Lancet Oncol. 2005 Nov;6(11):841-50.</citation>
    <PMID>16257791</PMID>
  </reference>
  <reference>
    <citation>Ghilezan MJ, Jaffray DA, Siewerdsen JH, Van Herk M, Shetty A, Sharpe MB, Zafar Jafri S, Vicini FA, Matter RC, Brabbins DS, Martinez AA. Prostate gland motion assessed with cine-magnetic resonance imaging (cine-MRI). Int J Radiat Oncol Biol Phys. 2005 Jun 1;62(2):406-17.</citation>
    <PMID>15890582</PMID>
  </reference>
  <reference>
    <citation>Padhani AR, Khoo VS, Suckling J, Husband JE, Leach MO, Dearnaley DP. Evaluating the effect of rectal distension and rectal movement on prostate gland position using cine MRI. Int J Radiat Oncol Biol Phys. 1999 Jun 1;44(3):525-33.</citation>
    <PMID>10348281</PMID>
  </reference>
  <reference>
    <citation>Litzenberg D, Dawson LA, Sandler H, Sanda MG, McShan DL, Ten Haken RK, Lam KL, Brock KK, Balter JM. Daily prostate targeting using implanted radiopaque markers. Int J Radiat Oncol Biol Phys. 2002 Mar 1;52(3):699-703.</citation>
    <PMID>11849792</PMID>
  </reference>
  <reference>
    <citation>Litzenberg DW, Balter JM, Hadley SW, Sandler HM, Willoughby TR, Kupelian PA, Levine L. Influence of intrafraction motion on margins for prostate radiotherapy. Int J Radiat Oncol Biol Phys. 2006 Jun 1;65(2):548-53. Epub 2006 Mar 20.</citation>
    <PMID>16545919</PMID>
  </reference>
  <reference>
    <citation>Vargas C, Yan D, Kestin LL, Krauss D, Lockman DM, Brabbins DS, Martinez AA. Phase II dose escalation study of image-guided adaptive radiotherapy for prostate cancer: use of dose-volume constraints to achieve rectal isotoxicity. Int J Radiat Oncol Biol Phys. 2005 Sep 1;63(1):141-9.</citation>
    <PMID>16111582</PMID>
  </reference>
  <reference>
    <citation>Vargas C, Martinez A, Kestin LL, Yan D, Grills I, Brabbins DS, Lockman DM, Liang J, Gustafson GS, Chen PY, Vicini FA, Wong JW. Dose-volume analysis of predictors for chronic rectal toxicity after treatment of prostate cancer with adaptive image-guided radiotherapy. Int J Radiat Oncol Biol Phys. 2005 Aug 1;62(5):1297-308. Review.</citation>
    <PMID>16029785</PMID>
  </reference>
  <reference>
    <citation>Taylor A, Rockall AG, Reznek RH, Powell ME. Mapping pelvic lymph nodes: guidelines for delineation in intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys. 2005 Dec 1;63(5):1604-12. Epub 2005 Sep 29.</citation>
    <PMID>16198509</PMID>
  </reference>
  <reference>
    <citation>Ehrenpreis ED, Jani A, Levitsky J, Ahn J, Hong J. A prospective, randomized, double-blind, placebo-controlled trial of retinol palmitate (vitamin A) for symptomatic chronic radiation proctopathy. Dis Colon Rectum. 2005 Jan;48(1):1-8.</citation>
    <PMID>15690650</PMID>
  </reference>
  <reference>
    <citation>Denton A, Forbes A, Andreyev J, Maher EJ. Non surgical interventions for late radiation proctitis in patients who have received radical radiotherapy to the pelvis. Cochrane Database Syst Rev. 2002;(1):CD003455. Review. Update in: Cochrane Database Syst Rev. 2016;4:CD003455.</citation>
    <PMID>11869662</PMID>
  </reference>
  <reference>
    <citation>Cavcić J, Turcić J, Martinac P, Jelincić Z, Zupancić B, Panijan-Pezerović R, Unusić J. Metronidazole in the treatment of chronic radiation proctitis: clinical trial. Croat Med J. 2000 Sep;41(3):314-8.</citation>
    <PMID>10962052</PMID>
  </reference>
  <reference>
    <citation>Delanian S, Lefaix JL. Current management for late normal tissue injury: radiation-induced fibrosis and necrosis. Semin Radiat Oncol. 2007 Apr;17(2):99-107. Review.</citation>
    <PMID>17395040</PMID>
  </reference>
  <reference>
    <citation>Lefaix JL, Delanian S, Vozenin MC, Leplat JJ, Tricaud Y, Martin M. Striking regression of subcutaneous fibrosis induced by high doses of gamma rays using a combination of pentoxifylline and alpha-tocopherol: an experimental study. Int J Radiat Oncol Biol Phys. 1999 Mar 1;43(4):839-47.</citation>
    <PMID>10098440</PMID>
  </reference>
  <reference>
    <citation>Delanian S, Porcher R, Balla-Mekias S, Lefaix JL. Randomized, placebo-controlled trial of combined pentoxifylline and tocopherol for regression of superficial radiation-induced fibrosis. J Clin Oncol. 2003 Jul 1;21(13):2545-50.</citation>
    <PMID>12829674</PMID>
  </reference>
  <reference>
    <citation>Spry N, Halkett G, Aoun S, Spry J, Yeoh E. Development of a European organization for research and treatment of cancer module to assess the quality of life of patients with proctitis after pelvic radiotherapy for malignancy. Int J Radiat Oncol Biol Phys. 2008 Oct 1;72(2):522-8. doi: 10.1016/j.ijrobp.2007.12.062. Epub 2008 Apr 18.</citation>
    <PMID>18374505</PMID>
  </reference>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 28, 2009</study_first_submitted>
  <study_first_submitted_qc>August 28, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2009</study_first_posted>
  <last_update_submitted>March 1, 2018</last_update_submitted>
  <last_update_submitted_qc>March 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Proton Radiation, Prostate Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

